EU IVDR Change Management and Notified Body Transfer: Articles 51, 53 and 54
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Change compliance under the IVDR runs along three lines. Article 51 governs the certificate itself: renewal under Article 51(2), restrictions and additional PMPF requirements under Article 51(3), suspension, revocation and restriction under Article 51(4), and public visibility of certificate status under Article 51(5). Article 53 governs the voluntary change of notified body: the manufacturer, the outgoing body and, where possible, the incoming body must conclude a written agreement covering the date the old certificate ceases to be valid, the last day the old body’s number may be affixed, the transfer of documentation, the date of handover of tasks, and the serial number or batch number of the last device placed on the market under the old number. Article 54 provides a derogation channel from the conformity assessment procedures. Handling these three lines in one coordinated plan prevents the most common change-management failures: certificate status and label numbering drifting apart during a notified body switch, and renewal projects started too late to fit inside the statutory review windows.
2. Legal basis
| Regulation / document | Provision | Dates | Source |
|---|---|---|---|
| Regulation (EU) 2017/746 (IVDR) | Articles 51(2)–(5) (validity and renewal, restrictions and PMPF requirements, suspension and revocation, public visibility of status); Article 53 (voluntary change of notified body); Article 54 (derogation from conformity assessment procedures) | Adopted 2017-04-05; applicable 2022-05-26 | EUR-Lex |
| Same regulation | Article 50(1) (notification of Class D certificates, excluding applications to supplement or renew existing certificates); Article 42 (changes to designation); Article 16 (consequences of changes where a person acts as manufacturer) | 2017-04-05 | EUR-Lex |
| Implementing Regulation (EU) 2026/977 | Review of planned changes 30 days, additional review 90 days, supplementary certificates 20 days; re-certification review 90 days | Applicable from 2027-02-25 | EUR-Lex |
3. Expert insights
Insight 1: The five elements of Article 53 determine whether the switch can be seamless.
The written agreement required by Article 53 must cover: the date on which the old certificate ceases to be valid, the deadline until which the number of the original notified body may be affixed to devices, the transfer of documentation, the date of handover of subsequent tasks, and, where applicable, the serial number or batch number of the last device produced under the old number. Missing any single element creates a window in which label numbering and certificate status are inconsistent on the market, which downstream customers and authorities alike will read as non-compliance. Companies that prepare all five dates in a single timeline, aligned with production and labelling plans, can execute a body change without pausing supply. Inventory positioning before the switch, so that stock produced under the old number can sell through within the agreed window, is the operational half of the same exercise.
Insight 2: Class D supplementing and renewal applications do not trigger the Article 50(1) notification.
Article 50(1) expressly excludes applications to supplement or renew existing certificates from the notification obligation for Class D certificates. This means that renewing a Class D certificate does not repeat the full competent authority notification process, but the certificate information must still be recorded in the Article 52 electronic system and made public under Article 51(5). Manufacturers should therefore keep the renewal workflow lean, while ensuring that the post-renewal data check in EUDAMED, including certificate scope and validity dates, is part of the standard closing step of the change process.
Insight 3: Article 54 is an exception channel, not an alternative route.
Article 54 allows, where the statutory conditions are met and with the approval of the competent authority, a derogation from the applicable conformity assessment procedure. Its nature differs fundamentally from the route selection between Annex IX and Annexes X plus XI under Article 48: the latter are parallel options open to any manufacturer, while the former is an exception requiring justification. Companies should not treat Article 54 as a routine way to save time under schedule pressure; misuse invites authority scrutiny of the very projects it was meant to expedite.
Insight 4: Regulation (EU) 2026/977 sets binding time limits for changes and re-certification.
From 2027-02-25, the review of planned changes is capped at 30 days, reviews requiring additional assessment at 90 days, and the issuing of supplementary certificates at 20 days; the re-certification review is capped at 90 days. In addition, where a manufacturer confirms in its quotation information for a change or re-certification that the core information previously submitted has not changed, the notified body may not request it again. These rules convert change management from a matter of negotiation with the notified body into a procedure with defined upper limits, which manufacturers can and should use to plan project timelines with confidence. They also give manufacturers a legitimate basis for escalating when a review exceeds its cap without justification.
4. Practical recommendations
- Maintain a change classification table mapping each type of change, whether affecting the certificate, the DoC, the technical documentation, the labelling or EUDAMED data, to its specific processing path.
- When changing notified body, draft the tripartite agreement around the five Article 53 elements, and schedule the labelling and DoC number switch against the agreed dates.
- Plan renewals backwards from the validity date stated on the certificate, and from 2027 onwards schedule against the 90-day re-certification review cap of Regulation (EU) 2026/977.
- Include a check of the public certificate status under Article 51(5) in the closing review of every change project.
- Initiate Article 54 only where statutory derogation conditions are genuinely met, and reserve lead time for the competent authority approval process.
5. Verification checklist
- □ A change classification table is in place covering certificates, DoC, technical documentation, labelling and EUDAMED data
- □ A notified body change has been executed with a written agreement covering the 5 elements of Article 53
- □ The labelling and DoC number switch is aligned with the agreement dates
- □ The renewal plan is adjusted to the 90-day re-certification cap of Regulation (EU) 2026/977 (from 2027-02-25)
- □ The public certificate status in the Article 52 electronic system has been re-checked (Article 51(5))
- □ The conditions for Article 54 have been confirmed to be exceptional
Legal information verified as of 29 October 2026.
GRZAN supports IVD manufacturers with change and certificate management under the IVDR: classifying changes and their processing paths, drafting Article 53 tripartite agreements for notified body switches, aligning labelling and DoC updates, and planning renewals and re-certifications against the time limits of Regulation (EU) 2026/977. For support with change management and notified body transitions, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us